CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 252 enrolled
Drug / intervention
nSTRIDE APS +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03182374
NCT03182374N/ACompleted

A Two-Phase, Multicenter, Randomized Study Comparing Autologous Protein Solution With Hyaluronic Acid Intra Articular Injections in Patients With Knee Osteoarthritis

Zimmer Biomet·interventional·Posted Jun 9, 2017·Updated Sep 19, 2024

In Brief

A clinical study evaluating nSTRIDE APS and Synvisc-One for Osteoarthritis, Knee. Completed, enrolled 252 participants across 14 sites in 10 countries.

Detailed Summary

This is a two-phase multicenter, double-blind, randomized, prospective evaluation of intra-articular injection(s) comparing APS to intra-articular HA injection(s). The maximum study duration for each subject will be 50 months; 48 months from treatment to last follow-up, and two additional months if the maximum visit window is realized. A total of 246 patients will be enrolled. These patients will meet specific inclusion and exclusion criteria, but can be generally characterized as patients with painful unilateral knee OA who have been unable to achieve satisfactory pain relief with previous conservative OA treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Denmark, Germany, Italy, Netherlands, Norway, Spain, Switzerland, Turkey (Türkiye), United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJun 9, 2017
Enrollment StartJul 14, 2017
Primary CompletionSep 30, 2019
Study CompletionJan 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.1 years ago

Interventions

nSTRIDE APSdevice

Intra-articular injection

Synvisc-Onedevice

Intra-articular injection